ReviewEndocrinology and metabolism clinics of North America2007
Interferon alpha treatment and thyroid dysfunction.
Review in Endocrinology and metabolism clinics of North America, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 3 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- KASL clinical practice guidelines: management of hepatitis C.Clinical and molecular hepatology · 2016Guideline
- KASL clinical practice guidelines: management of hepatitis C.Clinical and molecular hepatology · 2014Guideline
- Pooled it
- Thyroid function and ultrasound surveillance in childhood cancer survivors (CCS): a position paper of the Italian Society of Pediatric Endocrinology and Diabetology (ISPED).Journal of endocrinological investigation · 2026Review
- Two Cases of Chronic Central Serous Chorioretinopathy Successfully Treated with Systemic Interferon Alpha.Ocular immunology and inflammation · 2024Article
- Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease.The Journal of clinical endocrinology and metabolism · 2024Article
- Interferon autoantibodies as signals of a sick thymus.Frontiers in immunology · 2024Review
- Dual versus triple therapy in treatment of hepatitis C virus (HCV).Irish journal of medical science · 2023Article
- Association of interferon-based therapy with risk of autoimmune diseases in patients with chronic hepatitis C virus infection: A population-based Taiwanese cohort study.Frontiers in immunology · 2022Article
- Thyroid dysfunction is associated with the loss of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with α-interferon.The Journal of international medical research · 2021Article
- The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms.Blood research · 2021Review
- Programmable System of Cas13-Mediated RNA Modification and Its Biological and Biomedical Applications.Frontiers in cell and developmental biology · 2021Review
- Prevalence of Hypothyroidism in Patients With Erdheim-Chester Disease.JAMA network open · 2020Article
- ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Anticancer Drug-induced Thyroid Dysfunction.European endocrinology · 2020Review
- Autoimmune Thyroid Disease in Specific Genetic Syndromes in Childhood and Adolescence.Frontiers in endocrinology · 2020Review
- Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.BMC endocrine disorders · 2019Article
- Regulation ofFrontiers in immunology · 2019Article
- Effectiveness and safety of interferon α2a as an add-on treatment for refractory Behçet's uveitis.Therapeutic advances in chronic disease · 2019Article
- Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Interferon alpha (IFN alpha) is the cornerstone therapeutic agent for chronic hepatitis C virus (HCV) infection. Prospective studies have shown that up to 15% of HCV patients receiving IFN alpha develop clinical thyroid disease, and up to 40% become thyroid antibody positive. In some cases IFN-induced thyroiditis (IIT) may result in discontinuation of interferon therapy; thus, IIT represents a major clinical problem for hepatitis C patients receiving IFN alpha therapy. Recently, the mechanisms leading to the development of IIT have begun to be unraveled. It is now clear that HCV itself plays a role in the disease. Moreover, recent data suggest the IFN alpha precipitates thyroiditis by both immune modulatory mechanisms and direct thyroid toxic effects. Genetic factors also play a major role in the etiology of IIT. IIT can manifest both as clinical autoimmune thyroiditis (ie, Hashimoto's thyroiditis and Graves' disease) and as nonautoimmune thyroiditis (ie, destructive thyroiditis). Early detection and therapy of these conditions are important to avoid complications of thyroid disease such as cardiac arrhythmias. This article reviews the epidemiology and clinical manifestations of IIT and the mechanisms causing IIT, focusing on the role of HCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.